Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

NCT05762211 is registered in ClinicalTrials.gov with MaaT Pharma as lead sponsor.

NCT NCT05762211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05762211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)
Lead sponsor
MaaT Pharma
Phase
Phase 2
Overall status
Recruiting
Start date
October 31, 2023
Completion date
February 15, 2027
Enrollment
387 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

transplant complication